DE69928938T2 - Neues cyclosporin mit verbesserter wirkung - Google Patents
Neues cyclosporin mit verbesserter wirkung Download PDFInfo
- Publication number
- DE69928938T2 DE69928938T2 DE69928938T DE69928938T DE69928938T2 DE 69928938 T2 DE69928938 T2 DE 69928938T2 DE 69928938 T DE69928938 T DE 69928938T DE 69928938 T DE69928938 T DE 69928938T DE 69928938 T2 DE69928938 T2 DE 69928938T2
- Authority
- DE
- Germany
- Prior art keywords
- cyclosporin
- thr
- val
- meleu
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 title claims abstract description 55
- 108010036949 Cyclosporine Proteins 0.000 title claims abstract description 55
- 229930105110 Cyclosporin A Natural products 0.000 title claims abstract description 53
- 229960001265 ciclosporin Drugs 0.000 title claims abstract description 32
- 229930182912 cyclosporin Natural products 0.000 title claims abstract description 26
- 230000001976 improved effect Effects 0.000 title description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims description 9
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 7
- 208000030507 AIDS Diseases 0.000 claims description 6
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 101100241859 Mus musculus Oacyl gene Proteins 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- QHRMEJWWMGUKAM-LURJTMIESA-N (2s)-2-(ethylazaniumyl)-3-methylbutanoate Chemical compound CCN[C@@H](C(C)C)C(O)=O QHRMEJWWMGUKAM-LURJTMIESA-N 0.000 claims description 2
- 239000000243 solution Substances 0.000 description 32
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 108010072220 Cyclophilin A Proteins 0.000 description 18
- 102100034539 Peptidyl-prolyl cis-trans isomerase A Human genes 0.000 description 18
- 230000000694 effects Effects 0.000 description 15
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 14
- 241000725303 Human immunodeficiency virus Species 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 230000001506 immunosuppresive effect Effects 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 229910052786 argon Inorganic materials 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- 108010042955 Calcineurin Proteins 0.000 description 5
- 102000004631 Calcineurin Human genes 0.000 description 5
- AKCRVYNORCOYQT-YFKPBYRVSA-N N-methyl-L-valine Chemical compound CN[C@@H](C(C)C)C(O)=O AKCRVYNORCOYQT-YFKPBYRVSA-N 0.000 description 5
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 5
- 230000036436 anti-hiv Effects 0.000 description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 5
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- AHQFCPOIMVMDEZ-UNISNWAASA-N (e,2s,3r,4r)-3-hydroxy-4-methyl-2-(methylamino)oct-6-enoic acid Chemical compound CN[C@H](C(O)=O)[C@H](O)[C@H](C)C\C=C\C AHQFCPOIMVMDEZ-UNISNWAASA-N 0.000 description 4
- SNDPXSYFESPGGJ-UHFFFAOYSA-N 2-aminopentanoic acid Chemical compound CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 4
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical group CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 4
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- KSPIYJQBLVDRRI-WDSKDSINSA-N N-methyl-L-isoleucine Chemical compound CC[C@H](C)[C@H](NC)C(O)=O KSPIYJQBLVDRRI-WDSKDSINSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 108700004026 gag Genes Proteins 0.000 description 3
- 101150098622 gag gene Proteins 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108010068682 Cyclophilins Proteins 0.000 description 2
- 102000001493 Cyclophilins Human genes 0.000 description 2
- 108010036941 Cyclosporins Proteins 0.000 description 2
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- 108010076039 Polyproteins Proteins 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 230000001861 immunosuppressant effect Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000009696 proliferative response Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- XJODGRWDFZVTKW-LURJTMIESA-N (2s)-4-methyl-2-(methylamino)pentanoic acid Chemical compound CN[C@H](C(O)=O)CC(C)C XJODGRWDFZVTKW-LURJTMIESA-N 0.000 description 1
- 108010030583 (melle-4)cyclosporin Proteins 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- WDYVUKGVKRZQNM-UHFFFAOYSA-N 6-phosphonohexylphosphonic acid Chemical compound OP(O)(=O)CCCCCCP(O)(O)=O WDYVUKGVKRZQNM-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 238000011749 CBA mouse Methods 0.000 description 1
- 244000248349 Citrus limon Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 241001149960 Tolypocladium inflatum Species 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 229940124277 aminobutyric acid Drugs 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- HOPRXXXSABQWAV-UHFFFAOYSA-N anhydrous collidine Natural products CC1=CC=NC(C)=C1C HOPRXXXSABQWAV-UHFFFAOYSA-N 0.000 description 1
- -1 anti-inflammatory Substances 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- UTBIMNXEDGNJFE-UHFFFAOYSA-N collidine Natural products CC1=CC=C(C)C(C)=N1 UTBIMNXEDGNJFE-UHFFFAOYSA-N 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000010931 ester hydrolysis Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004362 fungal culture Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940087646 methanolamine Drugs 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- RPJPZDVUUKWPGT-FOIHOXPVSA-N nim811 Chemical compound CC[C@H](C)[C@@H]1N(C)C(=O)CN(C)C(=O)[C@H](CC)NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC1=O RPJPZDVUUKWPGT-FOIHOXPVSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960002898 threonine Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229960004295 valine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- C07K7/645—Cyclosporins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH140598 | 1998-07-01 | ||
| CH140598 | 1998-07-01 | ||
| PCT/IB1999/001232 WO2000001715A1 (fr) | 1998-07-01 | 1999-06-30 | Nouvelle cyclosporine ayant un profil d'activite ameliore |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69928938D1 DE69928938D1 (de) | 2006-01-19 |
| DE69928938T2 true DE69928938T2 (de) | 2006-08-17 |
Family
ID=4209677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69928938T Expired - Lifetime DE69928938T2 (de) | 1998-07-01 | 1999-06-30 | Neues cyclosporin mit verbesserter wirkung |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | USRE40987E1 (enExample) |
| EP (1) | EP1091975B1 (enExample) |
| JP (1) | JP4350898B2 (enExample) |
| CN (1) | CN1218958C (enExample) |
| AT (1) | ATE312843T1 (enExample) |
| AU (1) | AU759480B2 (enExample) |
| BR (1) | BR9911724A (enExample) |
| CA (1) | CA2335903C (enExample) |
| DE (1) | DE69928938T2 (enExample) |
| DK (1) | DK1091975T3 (enExample) |
| ES (1) | ES2255275T3 (enExample) |
| MX (1) | MXPA00013019A (enExample) |
| PT (1) | PT1091975E (enExample) |
| WO (1) | WO2000001715A1 (enExample) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU759480B2 (en) | 1998-07-01 | 2003-04-17 | Debiopharm S.A. | Novel cyclosporin with improved activity profile |
| AU2125300A (en) | 1999-02-05 | 2000-08-25 | Debiopharm S.A. | Cyclosporin derivatives and method for the production of said derivatives |
| WO2002085928A2 (fr) | 2001-04-20 | 2002-10-31 | Debiopharm S.A. | Cyclosporine modifiee utilisable en tant que pro-drogue et son utilisation |
| CA2518265A1 (en) | 2003-03-17 | 2004-09-30 | Albany Molecular Research, Inc. | Novel cyclosporins |
| GB0320638D0 (en) | 2003-09-03 | 2003-10-01 | Novartis Ag | Organic compounds |
| US20060035821A1 (en) * | 2004-08-16 | 2006-02-16 | Hunt Kevin W | Cyclosporin analogs for the treatment of immunoregulatory disorders and respiratory diseases |
| WO2006039163A2 (en) * | 2004-09-29 | 2006-04-13 | Amr Technology, Inc. | Cyclosporin alkyne analogues and their pharmaceutical uses |
| JP2008514702A (ja) * | 2004-09-29 | 2008-05-08 | エーエムアール テクノロジー インコーポレイテッド | 新規シクロスポリン類似体およびそれらの薬学的使用 |
| US7196161B2 (en) * | 2004-10-01 | 2007-03-27 | Scynexis Inc. | 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection |
| HRP20110169T1 (hr) * | 2004-10-01 | 2011-04-30 | Debiopharm S.A. | Upotreba [d-meala]3-[etval]4-ciklosporina za liječenje infekcija hepatitisom c |
| CA2583494C (en) * | 2004-10-01 | 2014-01-21 | Scynexis, Inc. | 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis c infection |
| WO2006041631A2 (en) | 2004-10-06 | 2006-04-20 | Amr Technology, Inc. | Novel cyclosporin alkynes and their utility as pharmaceutical agents |
| PL1853296T3 (pl) * | 2005-01-10 | 2012-12-31 | Debiopharm Sa | Zastosowanie cyklicznego undekapeptydu do wytwarzania leku do podawania w trakcie zdarzeń niedokrwienia mięśnia sercowego |
| KR20080059270A (ko) | 2005-09-30 | 2008-06-26 | 싸이넥시스, 인크. | Ｃ형 간염 감염의 치료 및 예방을 위한 방법 및 제약조성물 |
| DE602006020152D1 (de) * | 2005-09-30 | 2011-03-31 | Scynexis Inc | Arylalkyl- und heteroarylalkyl-derivate von cyclosporin a bei der behandlung und vorbeugung einer virusinfektion |
| PT1957518E (pt) * | 2005-10-26 | 2016-02-26 | Astellas Pharma Inc | Novos compostos peptídicos cíclicos |
| US7696165B2 (en) * | 2006-03-28 | 2010-04-13 | Albany Molecular Research, Inc. | Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders |
| US7696166B2 (en) * | 2006-03-28 | 2010-04-13 | Albany Molecular Research, Inc. | Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders |
| CN101511357B (zh) | 2006-05-19 | 2011-11-02 | 西尼克斯公司 | 环孢菌素类化合物及其组合物在制备治疗和预防眼部疾病的药物中的应用 |
| EP2027761A1 (fr) * | 2006-06-02 | 2009-02-25 | Claude Annie Perrichon | Gestion des electrons actifs |
| CN101108178B (zh) * | 2006-07-20 | 2010-09-15 | 复旦大学 | 一种亲环素a抑制剂在制备抗艾滋病药物中的应用 |
| BRPI0719189A2 (pt) * | 2006-10-12 | 2018-08-14 | Univ Kyushu Nat Univ Corp | uso de ciclosporinas modificadas |
| WO2008069917A2 (en) * | 2006-11-20 | 2008-06-12 | Scynexis, Inc. | Novel cyclic peptides |
| EP2124992A2 (en) * | 2007-01-04 | 2009-12-02 | Debiopharm S.A. | Non-immunosuppressive cyclosporin for treatment of ullrich congenital muscular dystrophy |
| WO2008127613A1 (en) * | 2007-04-11 | 2008-10-23 | Scynexis, Inc. | New pharmaceutical compositions |
| KR20100017547A (ko) * | 2007-05-02 | 2010-02-16 | 아스텔라스세이야쿠 가부시키가이샤 | 신규 시클릭 펩티드 화합물 |
| AU2008304313B2 (en) | 2007-09-26 | 2013-01-10 | Oregon Health & Science University | Cyclic undecapeptides and derivatives as multiple sclerosis therapies |
| WO2009098533A1 (en) * | 2008-02-08 | 2009-08-13 | Debiopharm Sa | Non -immunosuppressive cyclosporin for the treatment of muscular dystrophy |
| US20090306033A1 (en) * | 2008-06-06 | 2009-12-10 | Keqiang Li | Novel cyclic peptides |
| US9090671B2 (en) | 2008-06-06 | 2015-07-28 | Scynexis, Inc. | Macrocyclic peptides |
| DE102008060549A1 (de) | 2008-12-04 | 2010-06-10 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung |
| CA2748389A1 (en) | 2008-12-31 | 2010-07-08 | Scynexis, Inc. | Derivatives of cyclosporin a |
| KR20110111321A (ko) * | 2009-01-30 | 2011-10-10 | 이난타 파마슈티칼스, 인코포레이티드 | Ｃ형 간염을 예방하거나 치료하기 위한 사이클로스포린 유사체 |
| US8685917B2 (en) * | 2009-07-09 | 2014-04-01 | Enanta Pharmaceuticals, Inc. | Cyclosporin analogues |
| AU2010313497B2 (en) | 2009-10-30 | 2013-08-01 | Boehringer Ingelheim International Gmbh | Dosage regimens for HCV combination therapy comprising BI201335, interferon alpha and ribavirin |
| JP5536229B2 (ja) * | 2009-12-18 | 2014-07-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｈｃｖ併用療法 |
| WO2011076784A2 (en) | 2009-12-21 | 2011-06-30 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | New inhibitors of cyclophilins and uses thereof |
| WO2012009715A2 (en) | 2010-07-16 | 2012-01-19 | S&T Global Inc. | Novel cyclosporin derivatives for the treatment and prevention of a viral infection |
| US9573978B2 (en) | 2010-08-12 | 2017-02-21 | S&T Global, Inc. | Cyclosporin derivatives for the treatment and prevention of a viral infection |
| WO2012037485A2 (en) * | 2010-09-16 | 2012-03-22 | 1The Johns Hopkins University | Methods of inhibiting alphavirus replication and treating alphavirus infection |
| US9890198B2 (en) | 2010-12-03 | 2018-02-13 | S&T Global Inc. | Cyclosporin derivatives and uses thereof |
| JO3337B1 (ar) * | 2010-12-13 | 2019-03-13 | Debiopharm Sa | تركيبات صيدلية تشمل أليسبوريفير |
| KR102011339B1 (ko) | 2010-12-15 | 2019-08-16 | 콘트라빌 파마슈티컬스, 인코퍼레이티드 | 아미노산 1 및 3에서 변형된 사이클로스포린 유사체 분자 |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| ES2572329B1 (es) | 2011-10-21 | 2017-08-24 | Abbvie Inc. | Combinación de al menos dos agentes antivirales de acción directa y ribavirina pero no interferón, para uso en el tratamientodel vhc |
| PT107924A (pt) | 2011-10-21 | 2014-12-03 | Abbvie Inc | Tratamento de combinação de daa (eg. com abt-072 ou abt-333) para utilização no tratamento de hcv |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| AR090964A1 (es) | 2012-05-09 | 2014-12-17 | Novartis Ag | Proceso para la elaboracion de undecapeptidos ciclicos |
| EP2705856A1 (en) | 2012-09-07 | 2014-03-12 | Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. | Compounds for the treatment of neurodegenerative disorders |
| WO2014085623A1 (en) | 2012-11-28 | 2014-06-05 | Enanta Pharmaceuticals, Inc. | Novel [n-me-4-hydroxyleucine]-9-cyclosporin analogues |
| RU2016110247A (ru) | 2013-08-26 | 2017-10-02 | Энанта Фармасьютикалс, Инк. | Аналоги циклоспорина для предупреждения или лечения гепатита с |
| CN104744570A (zh) * | 2013-12-31 | 2015-07-01 | 深圳先进技术研究院 | 一种环孢菌素的合成方法 |
| WO2016073480A1 (en) | 2014-11-03 | 2016-05-12 | Enanta Pharmaceuticals, Inc. | Novel cyclosporin analogues for preventing or treating hepatitis c infection |
| CA3022119A1 (en) | 2016-04-28 | 2017-11-02 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
| EP4132558A1 (en) | 2020-04-06 | 2023-02-15 | Debiopharm International SA | Alisporivir for use in human viral infections |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH614931A5 (enExample) | 1975-11-04 | 1979-12-28 | Sandoz Ag | |
| US4210581A (en) | 1975-11-04 | 1980-07-01 | Sandoz Ltd. | Organic compounds |
| DE2819094A1 (de) | 1977-05-10 | 1978-11-23 | Sandoz Ag | Cyclosporin-derivate, ihre verwendung und herstellung |
| SE448386B (sv) | 1978-10-18 | 1987-02-16 | Sandoz Ag | Nya cyklosporinderivat, forfarande for framstellning av dem samt farmaceutisk komposition innehallande dem |
| IE54936B1 (en) | 1980-02-14 | 1990-03-28 | Sandoz Ltd | A method for the total synthesis of cyclosporins, novel cyclosporins and novel intermediates and methods for their production |
| US4396542A (en) | 1980-02-14 | 1983-08-02 | Sandoz Ltd. | Method for the total synthesis of cyclosporins, novel cyclosporins and novel intermediates and methods for their production |
| DE3047662C2 (de) | 1980-12-18 | 1985-02-21 | Karl M. Reich Maschinenfabrik GmbH, 7440 Nürtingen | Puffersystem bei Einschlaggeräten |
| DE3260468D1 (en) | 1981-01-09 | 1984-09-06 | Sandoz Ag | Novel cyclosporins |
| US5639724A (en) | 1984-07-24 | 1997-06-17 | Sandoz Ltd. | Cyclosporin galenic forms |
| AU589917B2 (en) | 1984-10-04 | 1989-10-26 | Novartis Ag | Monoclonal antibodies to cyclosporins |
| EP0194972B1 (en) | 1985-03-11 | 1992-07-29 | Sandoz Ag | Novel cyclosporins |
| US4814323A (en) | 1986-03-25 | 1989-03-21 | Andrieu J M | Process for the treatment and the prevention of AIDS and other disorders induced by the LAV/HTLV III virus |
| DE3884470T2 (de) | 1987-06-17 | 1994-03-10 | Sandoz Ag | Cyclosporine und deren Benutzung als Arzneimittel. |
| KR0148748B1 (ko) | 1988-09-16 | 1998-08-17 | 장 크라메르, 한스 루돌프 하우스 | 사이클로스포린을 함유하는 약학조성물 |
| DK0484281T4 (da) | 1990-11-02 | 2001-02-05 | Novartis Ag | Cyclosporiner |
| CN1141317C (zh) | 1995-07-17 | 2004-03-10 | 碳化学公司 | 有抗人体免疫缺损病毒作用的环孢菌素衍生物 |
| JP3089350B2 (ja) * | 1995-11-20 | 2000-09-18 | ギルフォード ファーマシューティカルズ インコーポレイテッド | シクロフィリンロタマーゼ活性の阻害剤 |
| FR2757522B1 (fr) | 1996-12-24 | 1999-01-29 | Rhone Poulenc Rorer Sa | Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent |
| FR2757520B1 (fr) | 1996-12-24 | 1999-01-29 | Rhone Poulenc Rorer Sa | Derive de cyclosporine, sa preparation et les compositions pharmaceutiques qui le contiennent |
| FR2757521B1 (fr) | 1996-12-24 | 1999-01-29 | Rhone Poulenc Rorer Sa | Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent |
| AU759480B2 (en) | 1998-07-01 | 2003-04-17 | Debiopharm S.A. | Novel cyclosporin with improved activity profile |
| GB0320638D0 (en) | 2003-09-03 | 2003-10-01 | Novartis Ag | Organic compounds |
| US7439277B2 (en) | 2005-05-19 | 2008-10-21 | Fina Technology, Inc. | In-situ preparation of hydroperoxide functionalized rubber |
-
1999
- 1999-06-30 AU AU43856/99A patent/AU759480B2/en not_active Expired
- 1999-06-30 WO PCT/IB1999/001232 patent/WO2000001715A1/fr not_active Ceased
- 1999-06-30 EP EP99926684A patent/EP1091975B1/fr not_active Expired - Lifetime
- 1999-06-30 BR BR9911724-0A patent/BR9911724A/pt not_active Application Discontinuation
- 1999-06-30 JP JP2000558116A patent/JP4350898B2/ja not_active Expired - Lifetime
- 1999-06-30 ES ES99926684T patent/ES2255275T3/es not_active Expired - Lifetime
- 1999-06-30 PT PT99926684T patent/PT1091975E/pt unknown
- 1999-06-30 DK DK99926684T patent/DK1091975T3/da active
- 1999-06-30 US US12/123,601 patent/USRE40987E1/en not_active Expired - Lifetime
- 1999-06-30 US US09/720,923 patent/US6927208B1/en not_active Ceased
- 1999-06-30 CN CNB998081558A patent/CN1218958C/zh not_active Expired - Lifetime
- 1999-06-30 DE DE69928938T patent/DE69928938T2/de not_active Expired - Lifetime
- 1999-06-30 MX MXPA00013019A patent/MXPA00013019A/es active IP Right Grant
- 1999-06-30 CA CA002335903A patent/CA2335903C/fr not_active Expired - Lifetime
- 1999-06-30 AT AT99926684T patent/ATE312843T1/de active
Also Published As
| Publication number | Publication date |
|---|---|
| ATE312843T1 (de) | 2005-12-15 |
| US6927208B1 (en) | 2005-08-09 |
| PT1091975E (pt) | 2006-05-31 |
| DK1091975T3 (da) | 2006-04-18 |
| CN1218958C (zh) | 2005-09-14 |
| EP1091975B1 (fr) | 2005-12-14 |
| JP4350898B2 (ja) | 2009-10-21 |
| CA2335903C (fr) | 2009-11-10 |
| JP2002519434A (ja) | 2002-07-02 |
| CN1308635A (zh) | 2001-08-15 |
| WO2000001715A1 (fr) | 2000-01-13 |
| MXPA00013019A (es) | 2003-07-14 |
| USRE40987E1 (en) | 2009-11-17 |
| BR9911724A (pt) | 2001-03-20 |
| ES2255275T3 (es) | 2006-06-16 |
| AU759480B2 (en) | 2003-04-17 |
| CA2335903A1 (fr) | 2000-01-13 |
| AU4385699A (en) | 2000-01-24 |
| DE69928938D1 (de) | 2006-01-19 |
| EP1091975A1 (fr) | 2001-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69928938T2 (de) | Neues cyclosporin mit verbesserter wirkung | |
| DE69124459T3 (de) | Zyklosporine | |
| US6809077B2 (en) | Cyclosporin analogs for the treatment of autoimmune diseases | |
| DE69832984T2 (de) | DEUTERIERtE und undeuterierte CYCLOSPORIN-ANALOGA UND IHRE VERWENDUNG ALS IMMUNMODULIERENDE AGENtIEN | |
| JP4477777B2 (ja) | 新規シクロスポリン | |
| DE3884470T2 (de) | Cyclosporine und deren Benutzung als Arzneimittel. | |
| DE3851268T2 (de) | Zyklische Peptolide. | |
| US6979671B2 (en) | Cyclosporins for the treatment of immune disorders | |
| DE60208180T2 (de) | Modifiziertes, als medikamentvorstufe anwendbares cyclosporin und dessen verwendung | |
| EP0067425A1 (de) | Gegebenenfalls geschützte Peptide, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel | |
| DE69028967T2 (de) | Cyclosporin- Derivate | |
| CH667274A5 (de) | Cyclosporine, ihre herstellung und diese enthaltende pharmazeutische zusammensetzungen. | |
| DE3888357T2 (de) | Cyclosporin-Derivate, die eine modifizierte Aminosäure auf Stellung 8 tragen. | |
| DE69003595T2 (de) | Mikroproteine, Verfahren zur Herstellung derselben und Anwendung dieser Mikroproteine als Arzneimittel. | |
| DE2725734C2 (enExample) | ||
| DE2822951A1 (de) | Neue polypeptide mit thymusaktivitaet oder antagonistischer aktivitaet und verfahren zu ihrer herstellung | |
| DE102004011988A1 (de) | Cyclosporinderivate und diese enthaltende pharmazeutische Zusammensetzungen | |
| EP0033384B1 (de) | Thymosin-alpha-1-Fragmente enthaltende Arzneimittel mit immunstimulierender Wirkung, und Thymosin-alpha-1-Fragmente | |
| DE2633976A1 (de) | Tripeptidderivate, verfahren zu ihrer herstellung sowie diese enthaltende arzneimittel | |
| EP0338437A2 (de) | Synthetische Vakzine gegen die Maul- und Klauenseuche und Verfahren zu deren Herstellung | |
| EP0424670B1 (de) | Neue ZNS-aktive Hexapeptide mit antiamnestischer Wirkung | |
| PL159763B1 (pl) | Sposób wytwarzania nowych cyklicznych peptolidów PL | |
| DD299043A5 (de) | Verfahren zur herstellung neuartiger oral wirksamer neuropsychopharmaka |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |